Pharming Group N.V. PHGUF
Set alert
0.95 USD 0.00 -0.05%
At close · Oct 30
0.9545 Day range 0.9545
0.929 52-week range 2.17
- YTD
- -42.15%
- 1 year
- -36.37%
- Open
- 0.9545
- Prev close
- 0.955
- Mkt cap
- 675.58M
- Vol
- 1.00K
- Avg vol
- 134
- EPS
- 0.02
- P/E
- 47.73
More statistics
- Low
- 0.9545
- High
- 0.9545
- Earnings
- Aug 1, 2024
Next earnings
Aug 1, 2024
Expected Aug 1, 2024. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 24, 2024 | Sep 1, 2024 | 0.00 | 0.00 | — | — |
| Aug 1, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | 0.00 | -0.02 | — | — |
| Mar 14, 2024 | Dec 1, 2023 | 0.00 | 0.00 | — | — |
| Oct 26, 2023 | Sep 1, 2023 | 0.00 | 0.01 | — | — |
| Aug 3, 2023 | Jun 1, 2023 | 0.00 | 0.00 | — | — |
News
- Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes
- Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
- FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.
- Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
- Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
- Pharming Group announces results of 2026 Annual General Meeting of Shareholders
- Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
- Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders
- Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026
- Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
Your note
Sign in to keep a note on PHGUF — it syncs with the Stock Master app.